Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More
ALEMBIC ACTAVIS |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ALEMBIC Mar-23 |
ACTAVIS Dec-18 |
ALEMBIC/ ACTAVIS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 87 | 16,126 | - | |
Low | Rs | 56 | 10,818 | - | |
Sales per share (Unadj.) | Rs | 5.0 | 3,955.8 | - | |
Earnings per share (Unadj.) | Rs | 3.1 | -1,274.2 | - | |
Cash flow per share (Unadj.) | Rs | 3.4 | 416.9 | - | |
Dividends per share (Unadj.) | Rs | 2.20 | 0 | - | |
Avg Dividend yield | % | 3.1 | 0 | - | |
Book value per share (Unadj.) | Rs | 80.9 | 16,315.7 | - | |
Shares outstanding (eoy) | m | 256.78 | 332.60 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 14.4 | 3.4 | 422.3% | |
Avg P/E ratio | x | 22.7 | -10.6 | -214.7% | |
P/CF ratio (eoy) | x | 21.0 | 32.3 | 64.8% | |
Price / Book Value ratio | x | 0.9 | 0.8 | 106.6% | |
Dividend payout | % | 70.1 | 0 | - | |
Avg Mkt Cap | Rs m | 18,298 | 4,480,758 | 0.4% | |
No. of employees | `000 | NA | 16.9 | 0.0% | |
Total wages/salary | Rs m | 240 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 77,851.4 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | -25,076.0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 1,272 | 1,315,689 | 0.1% | |
Other income | Rs m | 643 | 25,160 | 2.6% | |
Total revenues | Rs m | 1,915 | 1,340,849 | 0.1% | |
Gross profit | Rs m | 297 | 34,478 | 0.9% | |
Depreciation | Rs m | 67 | 562,428 | 0.0% | |
Interest | Rs m | 5 | 75,923 | 0.0% | |
Profit before tax | Rs m | 868 | -578,713 | -0.1% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 147,595 | 0.0% | |
Tax | Rs m | 62 | -7,334 | -0.8% | |
Profit after tax | Rs m | 806 | -423,784 | -0.2% | |
Gross profit margin | % | 23.4 | 2.6 | 891.4% | |
Effective tax rate | % | 7.1 | 1.3 | 561.8% | |
Net profit margin | % | 63.4 | -32.2 | -196.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 1,721 | 539,627 | 0.3% | |
Current liabilities | Rs m | 838 | 477,372 | 0.2% | |
Net working cap to sales | % | 69.4 | 4.7 | 1,467.0% | |
Current ratio | x | 2.1 | 1.1 | 181.7% | |
Inventory Days | Days | 5,038 | 20 | 25,728.4% | |
Debtors Days | Days | 673 | 66 | 1,014.5% | |
Net fixed assets | Rs m | 20,324 | 148,929 | 13.6% | |
Share capital | Rs m | 514 | 0 | - | |
Net worth | Rs m | 20,780 | 5,426,601 | 0.4% | |
Long term debt | Rs m | 0 | 1,910,903 | 0.0% | |
Total assets | Rs m | 22,046 | 8,483,012 | 0.3% | |
Interest coverage | x | 187.7 | -6.6 | -2,833.8% | |
Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
Sales to assets ratio | x | 0.1 | 0.2 | 37.2% | |
Return on assets | % | 3.7 | -4.1 | -89.7% | |
Return on equity | % | 3.9 | -7.8 | -49.7% | |
Return on capital | % | 4.2 | -4.8 | -86.7% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 389 | 470,046 | 0.1% | |
From Investments | Rs m | 73 | 258,229 | 0.0% | |
From Financial Activity | Rs m | -464 | -806,740 | 0.1% | |
Net Cashflow | Rs m | -2 | -78,073 | 0.0% |
Compare ALEMBIC With: ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
Compare ALEMBIC With: ALPA LAB IND SWIFT LA GENNEX LAB. VINEET LABORATORIES BIOCON
Asian markets traded lower, while the US stock indices ended higher overnight with the S&P 500 hitting a record closing high ahead of key economic data.